

# UC San Diego

## UC San Diego Previously Published Works

### Title

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.

### Permalink

<https://escholarship.org/uc/item/9wv4d29p>

### Journal

Scientific reports, 6(1)

### ISSN

2045-2322

### Authors

Du, Michael  
Zhang, Linna  
Scorsone, Kathleen A  
et al.

### Publication Date

2016-06-01

### DOI

10.1038/srep27458

Peer reviewed

# SCIENTIFIC REPORTS

OPEN

## Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine

Received: 23 March 2016

Accepted: 18 May 2016

Published: 10 June 2016

Michael Du, Linna Zhang, Kathleen A. Scorsone, Sarah E. Woodfield & Peter E. Zage

Children with aggressive neural tumors have poor survival rates and novel therapies are needed. Previous studies have identified nifurtimox and buthionine sulfoximine (BSO) as effective agents in children with neuroblastoma and medulloblastoma. We hypothesized that nifurtimox would be effective against other neural tumor cells and would be synergistic with BSO. We determined neural tumor cell viability before and after treatment with nifurtimox using MTT assays. Assays for DNA ladder formation and poly-ADP ribose polymerase (PARP) cleavage were performed to measure the induction of apoptosis after nifurtimox treatment. Inhibition of intracellular signaling was measured by Western blot analysis of treated and untreated cells. Tumor cells were then treated with combinations of nifurtimox and BSO and evaluated for viability using MTT assays. All neural tumor cell lines were sensitive to nifurtimox, and IC<sub>50</sub> values ranged from approximately 20 to 210  $\mu$ M. Nifurtimox treatment inhibited ERK phosphorylation and induced apoptosis in tumor cells. Furthermore, the combination of nifurtimox and BSO demonstrated significant synergistic efficacy in all tested cell lines. Additional preclinical and clinical studies of the combination of nifurtimox and BSO in patients with neural tumors are warranted.

Neural tumors, including tumors of both the central and peripheral nervous systems, are common in both adults and children and are often associated with aggressive disease and poor prognosis. Survivors of these neural tumors suffer from significant late effects from therapy. Neuroblastoma and medulloblastoma are among the most common forms of cancer seen in children, while glioblastoma is the most common and most aggressive malignant primary brain tumor that affects both adults and children. Patients with aggressive forms of these neural tumors have very poor outcomes, with limited responses to treatment and frequent relapses. While recently introduced treatment strategies, such as immunotherapy for upfront treatment of neuroblastoma and new molecular prognostication for medulloblastoma, have resulted in some improvement in patient outcomes, novel therapies continue to be sorely needed for the patients with these neural tumors.

Nifurtimox is a nitrofuran compound that has been used since the 1970's as a primary form of therapy for Chagas' disease, a parasitic infection caused by *Trypanosoma cruzi*<sup>1,2</sup>. Nifurtimox has been shown to act through production of reduced oxygen metabolites superoxide and hydrogen peroxide, for which the parasites have lower detoxification capacity<sup>1,3</sup>. Preclinical studies have also shown that nifurtimox treatment generates reactive oxygen species and inhibits neuroblastoma and medulloblastoma cell growth *in vitro* and *in vivo*<sup>4,5</sup>, and in early phase clinical trials, nifurtimox was well tolerated by children with relapsed neuroblastoma, with mild nausea, vomiting and anorexia being the most commonly observed side effects. Tumor responses were seen in patients treated with nifurtimox at a dose of 30 mg/kg/day both as a single agent and in combination with chemotherapy<sup>6</sup>.

Buthionine sulfoximine (BSO) is a selective inhibitor of  $\gamma$ -glutamylcysteine synthetase ( $\gamma$ -GCS), the rate limiting enzyme in glutathione (GSH) synthesis<sup>7</sup>. BSO has been shown to increase the efficacy of nifurtimox against *T. cruzi*<sup>8,9</sup> and has also been shown to be an effective modulator of GSH-mediated chemoresistance by increasing the *in vitro* cytotoxicity of alkylating agents and radiation<sup>10–14</sup>. BSO has been tested in animal studies and in human phase I trials for adults with solid tumors, with documented clinical responses in patients with melanoma,

Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX 77030, USA. Correspondence and requests for materials should be addressed to P.E.Z. (email: pzage@ucsd.edu)

ovarian carcinoma and small cell carcinoma of the lung treated with the combination of BSO and melphalan<sup>15,16</sup>. BSO was also shown to be effective against neuroblastoma tumor cells, both alone and in combination with melphalan<sup>17–19</sup>, and prior studies have reported that treatment of mice with human glioma and medulloblastoma xenograft tumors with BSO prior to melphalan resulted in increased survival<sup>20</sup>. Furthermore, a pilot clinical trial for treatment of children with recurrent neuroblastoma with BSO combined with melphalan demonstrated an 18% response rate<sup>21</sup>, suggesting a potential role for BSO in combination with other therapies for cancer patients.

Despite these prior studies, the efficacy of nifurtimox against other neural tumor cells has not been well characterized, and the efficacy of the combination of nifurtimox and BSO has not been fully explored in preclinical models of cancer. Based on the evidence for the potential efficacy of nifurtimox and BSO as single agents against neural tumors and the efficacy of the combination against *T. cruzi*, we hypothesized that nifurtimox would be effective against neural tumor cells alone and in combination with BSO.

## Materials and Methods

**Cells and culture conditions.** The neuroblastoma cell lines used in this study have been previously utilized by our laboratory<sup>22,23</sup>, and were either purchased from American Type Culture Collection (ATCC, www.atcc.org) or were generously provided by Susan Cohn (The University of Chicago Children's Hospital, Chicago, IL, USA), John Maris (Children's Hospital of Philadelphia, Philadelphia, PA, USA), or the Children's Oncology Group (COG) Cell Culture and Xenograft Repository (www.cogcell.org). Neural tumor cell lines U-87, U373, CHLA-02-ATRT and PFSK-1 were purchased from ATCC. Medulloblastoma cell lines Daoy and D283 were generously provided by Vidya Gopalakrishnan (The University of Texas MD Anderson Cancer Center, Houston, TX, USA). TC-71, 143B, MG-63, MMH-ES, RD-ES, SK-ES-1 and SK-N-MC cells were generously provided by Jason Yustein (Baylor College of Medicine, Houston, TX, USA). Cell lines were grown at 37 °C in 5% CO<sub>2</sub> in appropriate media (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Life Technologies, Grand Island, NY), L-glutamine, sodium pyruvate and non-essential amino acids (Sigma-Aldrich, St. Louis, MO). All cell lines were authenticated by DNA profiling prior to use.

**Therapeutic agents.** Nifurtimox was generously provided by MetronomX, Inc. (Houston, TX). A 70 mM stock solution was generated in DMSO (Sigma) and stored at –20 °C. Nifurtimox was diluted in PBS to appropriate concentrations immediately before use. BSO (Sigma) was diluted in water (50 mg/mL) and stored at –20 °C. BSO was warmed and diluted in PBS to appropriate concentrations immediately prior to use.


**Cell viability assays.** The viability of cells exposed to nifurtimox and BSO was determined using a modified methyl tetrazolium (MTT; Sigma) assay as previously described<sup>22,23</sup>. 0.5–1.0 × 10<sup>4</sup> cells/well of exponentially growing cells were plated in 96-well plates. 24 hours later, nifurtimox or BSO was added to each well at specified concentrations. After 72, 96, or 120 hours of continuous drug exposure, 15 µL of 5 mg/mL MTT was added to each well and the plates were incubated for 4 hours at 37 °C. Medium was replaced with 150 µL of DMSO and the optical density (OD) was measured at 550 nm using a microplate spectrophotometer (Anthos Analytical, Durham, NC). Cell numbers were estimated from OD measurements in individual wells. Relative cell viability was calculated by subtracting the background OD of media alone and then dividing by the OD of control wells. Replicates of three wells were used for each drug concentration and assays were duplicated on separate days. IC50 values were derived using best-fit trendlines and values calculated using the relevant curve-fit equations.

For combination studies using nifurtimox and BSO, average cell viability for each drug alone was calculated and plotted against individual drug concentrations. Cells were then plated as above, treated with the specified concentrations of nifurtimox and BSO (with separate 96-well plates for each combination) for 72 hours, with cell viability determined as above and combination indices calculated using CalcuSyn v2.11 software (Biosoft, Cambridge, UK).

**Inhibition of Signaling Assays.** Neural tumor cell lines were plated at approximately 80% confluency in 60 mm plates and allowed to adhere overnight. Plates were washed twice with PBS and incubated in media for three hours, followed by the addition of nifurtimox for 72 hours. Cells were washed with PBS and lysed with M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL) with protease inhibitor (Sigma) at the completion of each experiment. Lysates were centrifuged and supernatants were collected.

Protein concentration in each sample was measured using a protein assay dye reagent (Bio-Rad, Hercules, CA). 30–50 µg total denatured protein from each cell line was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA) using standard techniques. Membranes were blocked in Odyssey blocking buffer (Li-Cor, Lincoln, NE) for 1 hour at room temperature and then incubated with primary antibodies to total ERK (#4695, 1:1000; Cell Signaling, Danvers, MA, USA), phosphorylated ERK (#4370, 1:1000; Cell Signaling), total MEK (#9126, 1:1000; Cell Signaling), phosphorylated MEK (#9154, 1:1000; Cell Signaling), β-actin (#A3853, 1:5000; Sigma), or vinculin (ab129002, 1:2000; Abcam). All antibodies were diluted in Odyssey blocking buffer (Li-Cor) with 0.1% Tween-20. Bound primary antibodies were incubated for 1 hour at room temperature with IRDye800 conjugated affinity purified anti-rabbit or anti-mouse secondary antibody (1:2000; Rockland, Gilbertsville, PA) and the signal was visualized on an Odyssey infrared imaging system (Li-Cor).

**Apoptosis assays.** Apoptosis was measured using assays for DNA ladder formation and poly-ADP ribose polymerase (PARP) cleavage. For DNA ladder formation assays, neural tumor cells were plated in 6-well plates and allowed to adhere overnight. Cells were then washed twice with PBS, followed by the addition of nifurtimox for 24 hours. Cells were collected and incubated in cell lysis buffer (100 mM Tris pH 8.0, 50 mM EDTA and 1% SDS (w/v)) for 10 minutes at room temperature. The mixture was vortexed with protein precipitation buffer (6 M NaCl) at room temperature followed by centrifugation. Genomic DNA was precipitated from the supernatant



**Figure 1.** Effects of nifurtimox on tumor cell lines. (A) panel of neuroblastoma (A), CNS (B) and sarcoma (C) tumor cell lines were treated with increasing concentrations of nifurtimox for 72 hours and cell viability was determined by MTT assays. (D) IC50 values were calculated for each cell line.

with isopropyl alcohol. After centrifugation, the remaining DNA precipitate was washed with 70% ethanol. The final DNA was dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA) at 37 °C. A Nanodrop spectrophotometer (Thermo Scientific) was used to measure DNA concentrations. 5 μg of total genomic DNA was separated on a 1% agarose gel and photographed with a VersaDoc molecular imager (Bio-Rad).


For PARP cleavage assays, neural tumor cells were plated as above and exposed to nifurtimox for 72 hours. Treated and untreated control cells were washed and lysed as above and 30–50 μg total denatured protein from each cell line was separated by SDS-PAGE and transferred to nitrocellulose membranes as above. Membranes were blocked and incubated with primary antibodies to PARP1 (#9542, 1:500, Cell Signaling). After exposure to secondary antibodies as above, images were obtained using the Odyssey infrared imaging system.

## Results


**Neural tumor cell line sensitivity to nifurtimox.** In order to determine the efficacy of nifurtimox against neural tumor cells, a panel of established human tumor cell lines were tested for sensitivity *in vitro* to a range of concentrations of nifurtimox using MTT assays. IC50 values were calculated and ranged from 20 to 210 μM (Fig. 1). Increased exposure time resulted in slightly decreased IC50 values (Supplemental Fig. 1). NGP and U373 tumor cells were among the most sensitive cell lines to nifurtimox, while SK-N-BE(2) and Daoy cells were among the least sensitive (Fig. 1). Most cell lines had IC50 values <100 μM, including 8 of 11 tested neuroblastoma and 5 of 6 tested CNS tumor cell lines, suggesting that neural tumor cells were particularly sensitive to nifurtimox.

**Nifurtimox induces apoptosis and inhibits intracellular signaling in neural tumor cells.** Based on the efficacy of nifurtimox as a single agent in our initial testing (Fig. 1) and the known ability of nifurtimox to penetrate the blood brain barrier<sup>24,25</sup>, we pursued further studies of nifurtimox in neural tumor cell lines. In order to determine the mechanism of decreased neural tumor cell viability after treatment with nifurtimox, we performed assays for DNA ladder formation and for cleavage of PARP to establish whether nifurtimox treatment induced apoptosis. DNA ladders and PARP cleavage were evident in tumor cells after treatment with nifurtimox (Fig. 2), suggesting that the decreased viability of tumor cells after nifurtimox treatment was secondary to induction of apoptosis.

Activity of the RAS/MAPK signaling pathway has been linked to the pathogenesis of multiple cancers in both adults and children<sup>26</sup>. To determine whether treatment with nifurtimox resulted in inhibition of these downstream signaling pathways, U373, U87 and PFSK-1 neural tumor cell lines were harvested before and after nifurtimox treatment and Western blots for total and phosphorylated MEK and ERK were performed. Nifurtimox treatment resulted in loss of ERK phosphorylation in PFSK-1 cells and in increased phosphorylation of MEK



**Figure 2.** Nifurtimox treatment induces apoptosis in neural tumor cells. U373, U87 and PFSK-1 neural tumor cells were treated with nifurtimox at the concentrations shown and assayed by immunoblot for PARP cleavage (top) and by agarose gel electrophoresis for DNA ladder formation (bottom).




**Figure 3.** Nifurtimox treatment inhibits ERK phosphorylation in neural tumor cells. U373, U87 and PFSK-1 neural tumor cells were lysed at baseline (untreated) or after treatment with nifurtimox. Western blots were performed for total (ERK, MEK) and phosphorylated (pERK, pMEK) ERK and MEK. Vinculin was used as a protein loading control.

and ERK in glioblastoma cell lines at low doses of nifurtimox, followed by significant reduction of MEK and ERK phosphorylation at doses above the determined IC<sub>50</sub> values in these cell lines (Fig. 3).


**Neural tumor cell line sensitivity to BSO and to the combination of nifurtimox and BSO.** BSO has demonstrated antitumor activity in a number of preclinical cancer models of neural tumors<sup>17–20</sup>. In order to confirm the efficacy of BSO in neural tumor cell lines, 6 neuroblastoma, 2 glioblastoma, and 1 PNET cell line were treated with increasing concentrations of BSO, and viability was determined using MTT assays. BSO was effective against neural tumor cell lines, with IC<sub>50</sub> values ranging from 36 to 1071  $\mu$ M (Fig. 4), consistent with previously reported IC<sub>50</sub> values for BSO in other neuroblastoma cell lines<sup>18</sup>.

In order to determine whether BSO could enhance the efficacy of nifurtimox against neural tumor cells, the panel of neural tumor cell lines were treated with the combination of nifurtimox and BSO over a range of





**Figure 4. Effects of BSO on neural tumor cells.** Neural tumor cells were treated with increasing concentrations of BSO for 72 hours and cell viability was determined by MTT assays (A). (B) IC<sub>50</sub> values were calculated for each independent cell line.



**Figure 5. Combination indices for nifurtimox plus BSO in neural tumor cell lines.** Combination indices (CIs) were calculated for each cell line and isobolograms were generated using all calculated CIs for each individual cell line (left). CIs were then color coded and plotted for each individual cell line (right).

concentrations. In each of the 9 tested cell lines, cell viability was dramatically reduced with the combination of nifurtimox and BSO, compared to either drug alone (Supplemental Fig. 2). Furthermore, calculated combination indices were consistently  $<1$  for most tested dosing combinations in each of the 9 cell lines (Fig. 5), suggesting synergistic efficacy of nifurtimox and BSO in neural tumor cell lines.

## Discussion

New treatment strategies are clearly needed for patients with high-risk and recurrent neural tumors. We have demonstrated that the anti-trypanosomal agent nifurtimox is effective against neural tumor cells and is synergistic with the GSH inhibitor BSO. Nifurtimox treatment results in reduced ERK phosphorylation and in induction of apoptosis and our results suggest that nifurtimox alone and in combination with BSO may be effective for patients with all types of neural tumors, including neuroblastoma, glioblastoma and medulloblastoma.

Prior studies have demonstrated the efficacy of nifurtimox and BSO as single agents in selected neural tumor models<sup>4,5,17,18</sup>. Our results both confirm and expand these prior reports and demonstrate that nifurtimox is effective against a wide range of tumor cell types and that nifurtimox combined with BSO demonstrates synergistic drug efficacy. However, the specific disease subtypes and biologic prognostic features associated with responses to nifurtimox and BSO are currently unknown. We are currently investigating the associations with other biologic factors and signaling pathways with the responses of neural tumor cells to nifurtimox and BSO.

Oral nifurtimox has been used for long-term treatment of Chagas' disease in adults at doses of 8 to 10 mg/kg/day and in children at 15 to 20 mg/kg/day<sup>27</sup>. When used to treat an acute *T. cruzi* infection, nifurtimox is administered for 90 days, but for chronic infection nifurtimox treatment continues for 120 days or longer<sup>27,28</sup>. Nifurtimox-related toxicities in adults primarily include nausea, vomiting, diarrhea, anorexia and weight loss along with irritability, sleep disorders and peripheral neuropathies<sup>28</sup>. During long-term treatment, additional secondary side-effects have included tremors, muscle weakness, mild paresthesia and polyneuritis<sup>29,30</sup>. Unlike adult patients, infants and young children with Chagas' disease treated with nifurtimox only experience minor adverse events, including anorexia and diarrhea<sup>31,32</sup>. Toxicities observed in children with neuroblastoma treated with nifurtimox included anorexia, nausea, stomach pain, neuropathies, and seizures<sup>6</sup>, and pill compliance data showed that, on average, children treated with nifurtimox took 96.7% of their prescribed pills, showing that the treatment regimen could be easily followed. The maximum tolerated dose in this patient population was determined to be 30 mg/kg/day<sup>6</sup>.

We determined the efficacy of nifurtimox against a panel of neural tumor cell lines, with calculated IC50 values between 20 and 210  $\mu$ M, similar to previously published results<sup>4,5</sup>. In healthy adults, serum levels of nifurtimox reached 2.6  $\mu$ M after a single 15 mg/kg oral dose<sup>33,34</sup>, while peak serum levels in children with neuroblastoma treated with single agent nifurtimox at 30 mg/kg/day exceeded 1 mM<sup>6</sup>, suggesting that serum levels required for tumor cell effects in our *in vitro* models are clinically achievable in patients with neural tumors.

A key limitation of many potential novel therapies for both adults and children with intracranial tumors is the inability of these agents to penetrate the blood brain barrier (BBB). Nifurtimox has been previously shown to penetrate the BBB in preclinical models<sup>24,25</sup>, and nifurtimox has demonstrated efficacy in late stage African trypanosomiasis (African sleeping sickness), defined by the presence of active CNS infection<sup>35,36</sup>. It is unclear whether the penetrability of the BBB is similar in patients with infection compared to those with malignancies. However, nifurtimox has demonstrated efficacy in intracranial orthotopic models of neural tumors<sup>4,5</sup>, suggesting that nifurtimox may be able to penetrate the BBB and reach levels with antitumor efficacy in patients with glioblastoma and other intracranial tumors.

The mechanism(s) underlying the efficacy of nifurtimox in neural tumors is not fully understood. Nifurtimox is a nitroheterocyclic compound that undergoes cellular reduction to nitro anion free radicals, hydrogen peroxide, and superoxide free radicals, which generate intracellular reactive oxygen species (ROS), leading to antitrypanosomal efficacy<sup>37</sup>. Nifurtimox has also been shown to induce apoptosis via induction of ROS in the presence of catecholamines in neuroblastoma preclinical models<sup>5</sup>. However, the mechanisms of efficacy in tumor cells in the absence of catecholamines is not clear.

Glutathione (GSH) is a ubiquitous intracellular tri-peptide that acts as a key intracellular antioxidant to minimize damage to important cellular components caused by ROS such as free radicals, peroxides, and heavy metals. The antitumor activity of many chemotherapy agents depends upon the induction of ROS, and inhibition of GSH has been shown to increase the efficacy of chemotherapy<sup>38</sup>. As a selective inhibitor of  $\gamma$ -GCS, the rate limiting enzyme in GSH synthesis, BSO has been shown to deplete GSH both *in vitro* and *in vivo*<sup>10,11,18</sup>, and BSO-mediated depletion of GSH renders cells susceptible to alkylating agent-mediated DNA damage, anthracycline-mediated lipid peroxidation of the cellular membranes, and ionizing radiation<sup>16–18</sup>. Indeed, BSO has been shown to be synergistic with multiple chemotherapy agents<sup>10,11,38–45</sup>.

BSO has been shown to be cytotoxic for neuroblastoma cell lines *in vitro* due to increased ROS<sup>18,19</sup>, and BSO has been shown to enhance the efficacy of nifurtimox in a murine model of Chagas' Disease<sup>9</sup>, suggesting a likely mechanism for our observed synergistic efficacy with nifurtimox. Our determined IC50 values were similar to previously published values in similar cell lines<sup>18</sup> and were also within the range of serum BSO levels seen in adults and children treated with BSO<sup>21,46</sup>, suggesting that serum levels of BSO in our *in vitro* models are clinically achievable in patients with neural tumors.

We have demonstrated that nifurtimox is effective against neural tumor cells and is synergistic with BSO. All tested neural and non-neural tumor cell lines were sensitive to nifurtimox, and in neural tumor cells, nifurtimox treatment inhibited ERK phosphorylation and induced apoptosis. The combination of nifurtimox and BSO demonstrated synergistic efficacy in tested cell lines, and further preclinical studies of the combination of nifurtimox and BSO are warranted. Furthermore, the efficacy of this combination against neural tumor cells provides strong biological and clinical rationale for clinical testing of nifurtimox and BSO in patients with additional types of neural tumors.

## References

- Bern, C. Antitrypanosomal Therapy for Chronic Chagas' Disease. *New Engl J Med.* **364**, 2527–34 (2011).
- Rassi, A. Jr., Rassi, A. & Marin-Neto, J. A. Chagas disease. *Lancet.* **375**, 1388–402 (2010).
- Docampo, R. & Stoppani, A. O. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in *Trypanosoma cruzi*. *Arch Biochem Biophys.* **197**, 317–321 (1979).
- Saulnier Sholler, G. *et al.* Nifurtimox induces apoptosis of neuroblastoma cells *in vitro* and *in vivo*. *J Pediatr Hematol Oncol.* **31**, 187–193 (2009).
- Koto, K. S. *et al.* Antitumor Activity of Nifurtimox is Enhanced with Tetrathiomolybdate in Medulloblastoma. *Int J Oncol.* **38**, 1329–41 (2011).
- Saulnier Sholler, G. L. *et al.* A Phase 1 Study of Nifurtimox in Patients with Relapsed/Refractory Neuroblastoma. *J Pediatr Hematol Oncol.* **33**, 25–30 (2011).

7. Tew, K. D., Houghton, P. J. & Houghton, J. A. Modulation of glutathione. In *Preclinical and Clinical Modulation of Anticancer Drugs* (eds. Tew, K. D., Houghton, P. J. Houghton, J. A.) 13–77 (CRC Press 1993).
8. Faundez, M. *et al.* Buthionine Sulfoximine Increases the Toxicity of Nifurtimox and Benznidazole in *Trypanosoma cruzi*. *Antimicrob Agents Chemother.* **49**, 126–30 (2005).
9. Faundez, M. *et al.* Buthionine Sulfoximine Has Anti-*Trypanosoma cruzi* Activity in a Murine Model of Acute Chagas' Disease and Enhances the Efficacy of Nifurtimox. *Antimicrob Agents Chemother.* **52**, 1837–9 (2008).
10. Somfai-Relle, S., Suzukake, K., Vistica, B. P. & Vistica, D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. *Biochem Pharmacol.* **33**, 485–490 (1984).
11. Hamilton, T. C. *et al.* Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. *Biochem Pharmacol.* **34**, 2583–2586 (1985).
12. Louie, K. G. *et al.* Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. *Cancer Res.* **45**, 2110–2115 (1985).
13. Tsutsui, K. *et al.* Chemosensitization by buthionine sulfoximine *in vivo*. *Int J Radiat Oncol Biol Phys.* **12**, 1183–1186 (1986).
14. Saikawa, Y. *et al.* Enhancement of antitumor activity of cisplatin on human gastric cancer cells *in vitro* and *in vivo* by buthionine sulfoximine. *Jpn J Cancer Res.* **84**, 787–793 (1993).
15. Bailey, H. H. *et al.* Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. *J Clin Oncol.* **12**, 194–205 (1994).
16. O'Dwyer, P. J. *et al.* Depletion of glutathione in normal and malignant human cells *in vivo* by buthionine sulfoximine: clinical and biochemical results. *J Natl Cancer Inst.* **84**, 264–267 (1992).
17. Anderson, C. P. *et al.* Buthionine Sulfoximine Alone and in Combination with Melphalan (L-PAM) is Highly Cytotoxic for Human Neuroblastoma Cell Lines. *Eur J Cancer* **33**, 2016–9 (1997).
18. Anderson, C. P. *et al.* Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis. *Exp Cell Res.* **246**, 183–192 (1999).
19. Marengo, B. *et al.* Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-Induced Cytotoxic Effects in Neuroblastoma. *Free Radic Biol Med.* **44**, 474–82 (2008).
20. Friedman, H. S. *et al.* Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. *J Natl Cancer Inst.* **81**, 524–527 (1989).
21. Anderson, C. P. *et al.* Pilot Study of Intravenous Melphalan Combined with Continuous Infusion L-S,R-Buthionine Sulfoximine for Children with Recurrent Neuroblastoma. *Pediatr Blood Cancer* **62**, 1739–46 (2015).
22. Scorsone, K. S., Zhang, L., Woodfield, S. E., Hicks, J. & Zage, P. E. The Novel Kinase Inhibitor EMD1214063 Is Effective Against Neuroblastoma. *Invest New Drugs* **32**, 815–824 (2014).
23. Zhang, L., Scorsone, K., Woodfield, S. E. & Zage, P. E. Sensitivity of Neuroblastoma to the Novel Kinase Inhibitor Cabozantinib Is Mediated by ERK Inhibition. *Cancer Chemother Pharmacol.* **76**, 977–87 (2015).
24. Watson, C. P. *et al.* The Transport of Nifurtimox, an Anti-*Trypanosomal* Drug, in an *in vitro* Model of the Human Blood-Brain Barrier: Evidence for Involvement of Breast Cancer Resistance Protein. *Brain Res.* **1436**, 111–21 (2012).
25. Jeganathan, S. *et al.* The Distribution of Nifurtimox Across the Healthy and *Trypanosome*-Infected Murine Blood-Brain and Blood-Cerebrospinal Fluid Barriers. *J Pharmacol Exp Ther.* **336**, 506–15 (2011).
26. Samatar, A. A. & Poulidakos, P. I. Targeting RAS-ERK Signalling in Cancer: Promises and Challenges. *Nat Rev Drug Discov.* **13**, 928–42 (2014).
27. Solari, A. *et al.* Treatment of *Trypanosoma cruzi*-infected children with nifurtimox: a 3 year follow-up with PCR. *J Antimicrob Chemother.* **48**, 515–519 (2001).
28. Le Loup, G., Pialoux, G. & Lescure, F. X. Update in Treatment of Chagas Disease. *Curr Opin Infect Dis.* **24**, 428–34 (2011).
29. Wegner, D. H. G. & Rohwedder, R. W. The effect of nifurtimox in acute Chagas infection. *Arzneim Forsch.* **22**, 1624–1635 (1972).
30. Wegner, D. H. G. & Rohwedder, R. W. Experience with nifurtimox in chronic Chagas infection. *Arzneim Forsch.* **22**, 1635–1642 (1972).
31. Freilij, H. & Altcheh, J. Congenital Chagas' disease: diagnostic and clinical aspects. *Clin Infect Dis.* **21**, 551–5 (1995).
32. Garcia-Bournissen, F., Altcheh, J., Panchaud, A. & Ito, S. Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. *Arch Dis Child.* **95**, 224–8 (2010).
33. Paulos, C. *et al.* Pharmacokinetics of a nitrofurantoin compound, nifurtimox, in healthy volunteers. *Int J Clin Pharmacol Ther Toxicol.* **27**, 454–457 (1989).
34. Gonzalez-Martin, G. *et al.* The pharmacokinetics of nifurtimox in chronic renal failure. *Eur J Clin Pharmacol.* **42**, 671–673 (1992).
35. Bisser, S. *et al.* Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second-Stage *Trypanosoma brucei* gambiense Sleeping Sickness. *J Infect Dis.* **195**, 322–329 (2007).
36. Priotto, G. *et al.* Nifurtimox-eflornithine combination therapy for second-stage African *Trypanosoma brucei* gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. *Lancet.* **374**, 56–6 (2009).
37. Maya, J. D. *et al.* Mode of action of natural and synthetic drugs against *Trypanosoma cruzi* and their interaction with the mammalian host. *Comp Biochem Physiol A.* **146**, 601–20 (2007).
38. Meijer, C. *et al.* Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. *Cancer Res.* **52**, 6885–6889 (1992).
39. Green, J. A. *et al.* Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. *Cancer Res.* **44**, 5427–5431 (1984).
40. Dorr, R. T., Liddil, J. D. & Soble, M. J. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine- (SR)-sulfoximine on human and murine tumor cells. *Invest New Drugs.* **4**, 305–313 (1986).
41. Ozols, R. F. *et al.* Enhanced melphalan cytotoxicity in human ovarian cancer *in vitro* and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. *Biochem Pharmacol.* **36**, 147–153 (1987).
42. Jordan, J., d'Arcy Doherty, M. & Cohen, G. M. Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line. *Br J Cancer.* **55**, 627–631 (1987).
43. Evans, C. G., Bodell, W. J., Tokuda, K., Doane-Setzer, P. & Smith, M. T. Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard. *Cancer Res.* **47**, 2525–2530 (1987).
44. Skapek, S. X. *et al.* Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. *Cancer Res.* **48**, 2764–2767 (1988).
45. Thrall, B. D., Raha, G. A., Springer, D. L. & Meadows, G. G. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs. *Pigment Cell Res.* **4**, 234–239 (1991).
46. Bailey, H. H. *et al.* Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. *J Natl Cancer Inst.* **89**, 1789–1796 (1997).

## Acknowledgements

This study was supported by MetronomX, Inc. to PEZ in the form of study drug.



## Author Contributions

M.D., L.Z., K.A.S. and S.W. carried out experiments for the study and M.D. and P.E.Z. compiled the results, generated the figures for the paper and prepared the manuscript. P.E.Z. conceived the study, designed the experiments, directed the project and edited and submitted the manuscript. All authors read and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Du, M. *et al.* Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. *Sci. Rep.* 6, 27458; doi: 10.1038/srep27458 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>